The purpose of this review is to describe current concepts in the field of Less Invasive Surfactant Administration (LISA). The use of continuous positive airway pressure (CPAP) has become standard for the treatment of premature infants with respiratory problems throughout the world. However, if CPAP fails, technologies like LISA are needed that can combine surfactant delivery and spontaneous breathing with the support of noninvasive modes of ventilation.
INTRODUCTION
Modified natural surfactants have been in clinical use for the treatment of respiratory distress syndrome (RDS) for about 30 years [1, 2] . Replacement therapy with exogenous surfactant preparations derived from animal sources dramatically reduced RDS-related morbidity and mortality and became the most effective evidence-based therapy for RDS. In the first decade of replacement therapy, surfactant bolus administration during mechanical ventilation was the method of choice. In the 1990s, continuous positive airway pressure (CPAP) became increasingly popular especially in Scandinavia. In 1992, a 'small catheter surfactant delivery method' was described for the first time [3] . However, it was believed that at least a short interval of positive pressure ventilation was needed to move surfactant from the central airways to the lung periphery, so that the INSURE (Intubate SURfactant Extubate) method was developed [4] . However, with INSURE laryngoscopy, and intubation with a standard large diameter endotracheal tube are performed accompanied by analgesia and sedation. Following surfactant bolus administration, the infants are either ventilated with bag valve masks and/or connected to a mechanical ventilator delivering gas volumes with the help of positive pressure at least for a short interval. In that way, INSURE is different and more invasive than LISA.
When CPAP became more popular even for premature infants, it became evident that CPAP failure because of RDS, that is, surfactant deficiency, is common especially in the most immature infants [5] . This prompted the search for the LISA technique with the aim to effectively provide an adequate dose of surfactant while the infant is breathing spontaneously with the support of CPAP [6,7 & ]. The 'small diameter tube method' (synonym for LISA) was rediscovered, about 10 years after its initial description [3] by Kribs et al. [6] in Cologne and from 2003 onwards, LISA was also used in L€ ubeck. The German Neonatal Network (GNN) facilitated the initial randomized trials (AMV and NINSAPP trials) [8, 9] and additional observational studies on LISA [10 & ] that underlined that LISA was also ready for routine use in neonatal ICUs (NICUs). The cohort of LISA-treated infants documented in the GNN has increased to more than 5000 patients by now [7 & ].
More than 50% of all surfactant treatments are performed by LISA in Germany [7 & ] and the international interest in this technique has steeply increased with studies reporting LISA results from, for example, Austria, Australia, Turkey, Spain, Iran and China [11] [12] [13] [14] [15] [16] . Both the national German [17] and the recent European guidelines [18] for surfactant replacement therapy mention LISA as the method of choice for surfactant delivery in infants with RDS.
EFFECTS OF LESS INVASIVE SURFACTANT ADMINISTRATION
LISA has been shown to reduce the need for mechanical ventilation in the randomized controlled AMV [8] and NINSAPP [9] trials. An observational study using a matched pairs design in more than 1000 infants demonstrated that this effect is robust in clinical practice also outside the specific setting of trials [10] . The effectiveness of LISA in preventing mechanical ventilation in the first 72 h strongly depends on gestational age [10] . Some of the most immature infants need intubation after the first days of life, mainly because of apnoea and/or muscular fatigue. However, the low intracranial hemorrhage (ICH) rate, for example, in the LISA group of the NINSAPP trial points [9] into the direction that postnatal circulatory adaptation under spontaneous breathing is of potential advantage also for the tiniest infants.
Metaanalyses [19] [20] [21] point out that LISA is superior to CPAP alone or the INSURE technique both in terms of avoidance of bronchopulmonary dysplasia (BPD) and ICH [19] . However, the quality of some of the studies included in these metaanalyses was questionable, so that further confirmative randomized controlled studies (RCT) are still needed.
HOW TO PRACTICE LESS INVASIVE SURFACTANT ADMINISTRATION
Prenatal lung maturation with corticosteroids and good obstetrical care are very important factors for spontaneous breathing directly after birth, which is a prerequisite to make LISA work. Infants who are not crying/breathing are stabilized with a mask and distending pressure after delivery. Most centers use CPAP at 6-9 cmH 2 O after birth with a variety of different devices, whereas sustained inflations are not current practice. The use of high-flow nasal cannula (HFNC) is increasing in popularity, but in Germany, still uncommon in the delivery suite as CPAP seems to allow higher distending pressures. Giving regard to the low physiological saturation limits, adaptation to postnatal life is allowed with as little intervention as possible. Gentle stimulation, late cord clamping, caring for patency of the airways (often a lateral position is more adequate than keeping the baby in a strictly supine position), avoiding unnecessary suctioning, maintenance of body temperature and avoiding stress as much as possible are of utmost importance to establish effective spontaneous breathing. By now, the majority of infants below 1000 g in Germany receive caffeine for stimulation of breathing/apnoea prevention already in the delivery suite, although there is no clear evidence from RCTs supporting this approach. In this way, LISA is not simply a single technical procedure but rather a component of a complex care bundle supporting the individual capacity of a premature
KEY POINTS
LISA allows combining surfactant delivery with spontaneous breathing.
LISA allows maintained laryngeal function.
LISA has the potential to improve patient comfort by avoiding mechanical ventilation.
LISA improves outcomes when compared with mechanical ventilation, other modes of noninvasive ventilation or short-time intubation and surfactant instillation (INSURE).
baby to adapt to extrauterine life (so called: minimal handling approach or 'soft landing').
If respiratory distress becomes evident shortly after birth, as indicated by increasing oxygen demand and/or tachypnoea, grunting and/or retractions, surfactant deficiency is likely and surfactant may be delivered by LISA already in the delivery room. The more stable, often also more mature, infants are transferred to the NICU under CPAP therapy and often receive surfactant only when certain thresholds in oxygen demand are reached (often a fraction of inspiratory oxygen (FiO 2 ) greater than 0.30 or greater than 0.40 is used as indication limit, also considering the gestational age (see e.g. [18] ).
For the most immature infants (e.g. <25 weeks of gestational age) some centers follow a (quasi-) prophylactic LISA approach and use LISA as early as at 20 min of life with the argument that in these infants with very delicate lung structures, surfactant treatment should be given as early as possible and most infants in this age group would receive surfactant anyhow in the hours to come. Clearly, RCTs are needed addressing the question of the superiority of such a 'prophylactic' approach compared with waitful watching and 'rescue' LISA treatment, if indicated.
In Germany, mainly thin (3.5-5.0 French) and soft catheters (e.g. gastric tubes, suction catheters, umbilical arterial or bladder catheters) are used for LISA and are mostly introduced into the larynx with the help of a laryngoscope and a Magill forceps (see also Fig. 1 ). Video laryngoscopy [22] holds some promise for well tolerated placement of the catheters in the trachea and also for teaching (see also Fig. 2 ). However, most neonatologists will tend to remove the laryngoscope for comfort reasons as soon as possible securing the adequate catheter position with the fingers on the lips/the nose of the babies. In the tiniest infants, the catheter is introduced only 1-2 cm beyond the vocal cords. Some gastric catheters have the disadvantage of side holes that are rather distant from the tip. Side holes/ not inserting the catheter deep enough carries the risk of increased surfactant reflux, whereas too deep insertion of the catheter may result in unilateral surfactant deposition. The surfactant instillation is done in small boluses and only slowed down when bradycardia, apnoea or increased surfactant reflux is observed. Some air is often placed in the syringe 'behind/on top of the surfactant' to allow removal of the surfactant from the dead space in the syringe and the catheter. As silicone oil may bind to the FIGURE 1. Devices for surfactant instillation by the standard and the less invasive surfactant administration method. From left to right: endotracheal tube size 2.5 (outer diameter 4.1 mm, see also Fig. 2a ), soft suction catheter 5 French (outer diameter: 1.7 mm see also Fig. 2b ), stiffer straight catheter (Lisacath) (outer diameter 1.7 mm) and special device (Neofact) with 3.5 French (outer diameter: 1.2 mm) catheter that is sliding out from the tip. Lisacath and Neofact have special 'softer' tips to avoid injury. surfactant lipids, it is preferable to use syringes that contain no lubricated rubber parts [23] .
Surfactant has unique spreading properties once it is instilled in the large airways. From animal experiments, it is known that infusing surfactant at too slow rates results in less even distribution compared with the bolus approach [24] . The surfactant instillation with LISA can usually be completed in less than 60 s. Rarely, 2 min or more are needed, when intermittent bradycardia/apnoea occurs and the injection has to be slowed down. There are no data comparing different speeds of surfactant delivery with LISA.
Mainly animal-derived modified natural surfactants have been studied for LISA. The AMV study [8] compared three different types of surfactant but was underpowered for valid comparisons in terms of LISA effectiveness between different surfactants. The AMV-trial [8] used a phospholipid dose of 100 mg/kg, the NINSAPP trial [9] a whole vial of 120 mg porcine surfactant per infant and a retrospective study a dose of 200 mg/kg [11] . In daily practice, often whole vials of surfactant are used, especially when treatment is done in the delivery room and an exact weight is not available. The pragmatic way to use a whole vial of, for example, 120 mg surfactant in a baby with an estimated weight of 800 g will result in a phospholipid dose of at least 150 mg/kg. There is hope that such a dose results in higher surfactant pool size than the 100 mg/kg used, for example, in the AMV study, where the rest of the vial content was discarded. Most studies report the need for retreatment in 20-30% of LISA-treated infants. Theoretically, a higher initial surfactant dose should supply a higher surfactant pool and hopefully thereby reduce the need for (stressful) retreatment. Again, clearly RCTs are needed here as well, before definitive dose recommendations can be made.
Given special experience, LISA can be successfully applied in infants as immature as 22 weeks [25] . Personally, we do not favour the use of LISA in infants above 32 weeks. There is no evidence for a benefit of LISA in this group so far and the risk for BPD is low in this group [13] . More mature infants often struggle, and therefore, need sedation/analgesia to tolerate the procedure. On the other hand, medication interferes with the spontaneous breathing that is crucial to make LISA work.
CATHETER TYPES
A variety of catheter types and instruments are used for the LISA procedure (see Table 1 and Fig. 1) . The placement of a soft catheter with the help of the Magill forceps is the method that most centers in Germany use. The catheter is often introduced via the mouth and has already been mounted into the forceps before the start of the procedure. Alternatively, the soft flexible catheter is introduced via the nose (while a mononasal CPAP is in place in the other nostril) and then taken up with the forceps similar to the technique of nasal intubation. Soft catheter introduction without a forceps has been described as the so-called Take Care procedure [15] . Not all neonatologists are familiar with nasal intubation and the use of a Magill forceps. Oral intubation is much more common in other parts of the world, so that direct laryngoscopy and the use of a stiff vascular catheter was described by Peter Dargaville as the so called Hobart method (MIST, minimal invasive surfactant therapy) in 2011 [27] .
By now, companies have developed straight [33 & ] (Lisacath) or catheters with an angulated tip (Surfcath) that are easy to use via the oral route. These catheters are relatively stiff, so that no extra devices are needed to introduce the tip through the vocal cords. Special introducers [28] (Neocath) allowing to slide out a soft thin catheter from the tip after the device has been placed in front of the larynx and devices to guide the catheter during video laryngoscopy have recently reached the market.
WHAT MAKES LESS INVASIVE SURFACTANT ADMINISTRATION DIFFERENT?
LISA is different from other modes of surfactant delivery as it allows the infant to keep on breathing and to use the physiological function of the larynx without (nearly complete) obstruction by a larger diameter endotracheal tube. Figure 2a demonstrates how the glottis is nearly completely obstructed by a size 2.5 endotracheal tube (inner diameter 2.5 mm, outer diameter 4.1 mm) in a mannequin airway simulating a 1000 g baby, whereas a small diameter catheter (e.g. 5 French, external diameter: 1.7 mm) leaves most of the airway open allowing flow of gas through the vocal cords with the catheter in place ( Fig. 2b) . A 5-French tube occludes a cross sectional area of approximately 1.8 mm 2 . A standard endotracheal size 2.5 tube has a total cross sectional area of 13.2 mm 2 . It must be emphasized that only 4.9 mm 2 of this area is are available for respiration. The rest (8.3 mm 2 ) is occluded by the wall of the endotracheal tube [34] .
Videos demonstrate that such small catheters allow movements of the vocal cords (e.g. Lancet TV: https://www.youtube.com/watch?-v=IYf92NN1kV0).
Recently, the use of a 2.0 endotracheal tube (the smallest available size) has been described for LISA [35] but still this corresponds to an outer diameter of 8 French (2.7 mm).
UNANSWERED QUESTIONS
In addition to the technical issues, the dose question and the matter of exact indications/treatment thresholds for different groups of patients, there is an ongoing debate whether analgesia and sedation during the LISA procedure is necessary, or may actually endanger the success of the method.
Analgesia and sedation during the less invasive surfactant administration procedure
It has to be stated clearly that the use of LISA does not exclude analgesia and/or sedation per se. Stress and pain in the neonatal period may have long-term negative effects and should be avoided whenever possible. Currently, in Germany, in infants less than 26 weeks, most centres will do the first LISA attempt without analgesia [25] . If the infant struggles, analgesia and sedation is used for the second attempt. For review see [32 && ].
Nonpharmacological methods of analgesia like positioning, holding, ('facilitated tucking') and/or sucrose solutions are often used. In more mature and vigorous infants, it seems wise to use analgesia and sedation right away. So far, there is no ideal combination of drugs that would allow analgesia and sedation with a rapid onset, a short duration, no suppression of spontaneous breathing and a favourable overall short and long-term safety profile. This is reflected by the fact that a variety of drugs have been studied for the purpose of analgesia/sedation during INSURE or LISA; fentanyl, ketamine and propofol were the most frequently used medications. First studies indicate that these drugs may help to reduce pain scores, but on the other hand, interfere with spontaneous breathing and increase the number of infants that need respiratory support/ mechanical ventilation during LISA [36 && ]. Thus, practice patterns of using these drugs vary widely between countries and NICUs [37] .
Short-term side effects
Under the condition that LISA is performed by neonatologists experienced in airway management, there are few acute side effects. Failure to insert the catheter through the vocal cords at first attempt, significant surfactant reflux, acute desaturations, bradycardia and/or need for positive pressure ventilation during LISA were observed in less than 10% [8] to more than 30% [13] of LISA/MIST manipulations. Short apnoea, hypoxia and bradycardia can often be handled by slowing down the injection speed/interrupting the surfactant administration or, if needed, by a couple of manual breaths via a CPAP device that in our experience should stay in place during the LISA procedure. Studies with continuous monitoring of saturation and regional (e.g. also cerebral) saturation by nearinfrared spectroscopy (NIRS) seem to indicate that the laryngoscopy is more often the source of side effects than the surfactant instillation itself [38] . The only potential adverse effect observed so far was a slight increase in the rate of focal intestinal perforation (FIP) in a subset of infants born at 23 and 24 weeks of gestation receiving LISA [39] . This finding may be related to the distension of the fragile intestinal wall in consequence the positive end-expiratory pressure applied during noninvasive ventilation, but clearly this has to be followed in more detail.
Long-term outcome
In individual studies [8, 9] and metaanalyses [19, 21] LISA reduces the incidence of ICH and BPD, and thus, bears the potential to improve also the longterm outcome. Small retrospective follow-up studies on LISA infants suggested favourable neurocognitive outcome compared with historical controls [40] [41] [42] [43] . Unpublished data from the 5-year followup of LISA infants in the GNN cohort suggest better lung function (FEV 1 ) and better neuro-outcome/ intellectual properties (WPPSI score) in infants who received surfactant via LISA compared with infants who received surfactant via the standard route. Follow-up results from the randomized studies will soon become available.
CONCLUSION
LISA is part of the strategy of a minimal handling approach supporting the concept of spontaneous breathing. LISA reduces the need for mechanical ventilation, and is therefore, in increasing use in NICUs around the world [44-50,51 & ]. Short-term (ICH and BPD) and first long-term follow-up data on neurocognitive and pulmonary function are encouraging. The search for better strategies allowing to deliver surfactant in an even gentler way goes on. In this context, especially surfactant nebulization may become one of the options on the horizon.
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